XML 33 R13.htm IDEA: XBRL DOCUMENT v3.6.0.2
Marketable Securities
12 Months Ended
Dec. 31, 2016
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
December 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,183,945

 
$

 
$

 
$
1,183,945

Total cash and cash equivalents
$
1,183,945

 
$

 
$

 
$
1,183,945

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (matures within 1 year)
$
15,506

 
$
2

 
$

 
$
15,508

Corporate equity securities (matures within 1 year)
43,213

 
21,347

 

 
64,560

Commercial paper (matures within 1 year)
59,331

 
73

 

 
59,404

Corporate debt securities (matures within 1 year)
111,225

 

 
(85
)
 
111,140

Total marketable securities
229,275

 
21,422

 
(85
)
 
250,612

Total cash, cash equivalents and marketable securities
$
1,413,220

 
$
21,422

 
$
(85
)
 
$
1,434,557

 
 
 
 
 
 
 
 
December 31, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
582,352

 
$

 
$

 
$
582,352

Government-sponsored enterprise securities
85,994

 

 

 
85,994

Commercial paper
34,889

 

 

 
34,889

Corporate debt securities
11,533

 

 

 
11,533

Total cash and cash equivalents
$
714,768

 
$

 
$

 
$
714,768

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (matures within 1 year)
$
87,176

 
$

 
$
(14
)
 
$
87,162

Commercial paper (matures within 1 year)
98,877

 
246

 

 
99,123

Corporate debt securities (matures within 1 year)
141,515

 

 
(106
)
 
141,409

Total marketable securities
327,568

 
246

 
(120
)
 
327,694

Total cash, cash equivalents and marketable securities
1,042,336

 
246

 
(120
)
 
1,042,462


The Company has a limited number of marketable securities in insignificant loss positions as of December 31, 2016, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in 2016, 2015 or 2014.